Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Exanta

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other… Expand
Review
2005
Review
2005
  • C. Boos, G. Lip
  • Expert review of cardiovascular therapy
  • 2005
  • Corpus ID: 20212567
Atrial fibrillation is the most common sustained cardiac arrhythmia and the most frequently encountered cause of embolic stroke… Expand
2005
2005
Thrombosis is the leading cause of death from heart attacks and strokes. Warfarin (coumadin), the only marketed oral… Expand
Review
2004
Review
2004
It is rare for any drug introduced more than 50 years ago to remain unsurpassed today; yet the oral prevention and treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
INTRODUCTION The effect of the oral direct thrombin inhibitor (DTI) ximelagatran (Exanta, AstraZeneca) on the endogenous thrombin… Expand
2004
2004
Ximelagatran (Exanta™, AstraZeneca), an oral direct thrombin inhibitor for the prevention and treatment of thromboembolic… Expand
Review
2004
Review
2004
Thromboembolic disorders continue to be a major cause of morbidity and mortality, resulting in an increased need for… Expand
2003
2003
  • O. Glynn
  • International journal of clinical practice
  • 2003
  • Corpus ID: 36614347
The phase III trial EXPRESS was a randomised, double-blind comparison of two anticoagulant therapies used as prophylaxis against… Expand
Review
2003
Review
2003
  • S. Haas
  • Thrombosis research
  • 2003
  • Corpus ID: 25095850
There are many well-known drawbacks associated with the currently used antithrombotic agents, warfarin, heparin, and low… Expand
Review
2003
Review
2003
The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its… Expand